Form 4 for ORGO Organogenesis Holdings Inc.
Accepted 2025-02-21 00:00:00 ET · period of report 2025-02-19 · accession 0001062993-25-003228 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-21 | 2025-02-19 | ORGO | Grow Brian | Chief Commercial Off | A - Grant | $0.00 | +183.1K | 670.5K | +38% | $0 |
| D | 2025-02-21 | 2025-02-19 | ORGO | Grow Brian | Chief Commercial Off | A - Grant | $0.00 | +189.4K | 189.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-02-19 | A | A | 183,067 | $0.00 | 670,490 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-02-19 | A | A | 189,369 | $0.00 | 189,369 | D | $3.53 · — to 2035-02-19 | 189,369 Class A Common Stock | (F2) The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. |